(19)
(11) EP 1 715 865 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Mention of the grant of the patent:
10.03.2010 Bulletin 2010/10

(21) Application number: 05710692.4

(22) Date of filing: 18.02.2005
(51) International Patent Classification (IPC): 
A61K 31/47(2006.01)
A61P 3/06(2006.01)
 A61K 31/202(2006.01)
(86) International application number:
PCT/JP2005/003092
(87) International publication number:
WO 2005/079797 (01.09.2005 Gazette 2005/35)

(54)

HYPERLIPEMIA THERAPEUTIC AGENT COMPRISING PITAVASTATINS AND EICOSAPENTAENOIC ACID

MITTEL ZUR BEHANDLUNG VON HYPERLIPIDÄMIE MIT PITAVASTATINEN UND EICOSAPENTAENSÄURE

AGENT THERAPEUTIQUE CONTRE L HYPERLIPÉMIE CONTENANT DES PITAVASTATINES ET L'ACIDE EICOSAPENTAÉNOÏQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 19.02.2004 US 780640

(43) Date of publication of application:
02.11.2006 Bulletin 2006/44

(73) Proprietors:
  • Kowa Company, Ltd.
    Nagoya-shi, Aichi-ken 460-8625 (JP)
  • Nissan Chemical Industries, Ltd.
    Chiyoda-ku, Tokyo 101-0054 (JP)

(72) Inventors:
  • AOKI, Taro
    Tokorozawa-shi, Saitama 3590037 (JP)
  • YAMAGUCHI, Junji
    Higashimurayama-shi, Tokyo 1890022 (JP)
  • SASAKI, Yusuke
    Higashimurayama-shi, Tokyo 1890022 (JP)

(74) Representative: Hartz, Nikolai et al
Wächtershäuser & Hartz Patentanwaltspartnerschaft Weinstrasse 8
80333 München
80333 München (DE)


(56) References cited: : 
   
  • "PITAVASTATIN ITAVASTATIN, NISVASTATIN, NK 104, NKS 104, P 872441" DRUGS IN R & D, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 3, no. 1, 2002, pages 58-60, XP008058974 ISSN: 1174-5886
  • NORDOEY A ET AL: "N-3 POLYUNSATURATED FATTY ACIDS AND CARDIOVASCULAR DISEASES" LIPIDS, CHAMPAIGN, IL, US, vol. 36, no. SUPPL, 2001, pages S127-S129, XP008060642 ISSN: 0024-4201
  • DAS U N: "ESSENTIAL FATTY ACIDS AS POSSIBLE MEDIATORS OF THE ACTIONS OF STATINS" PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 65, no. 1, July 2001 (2001-07), pages 37-40, XP008060638 ISSN: 0952-3278
  • NORDOY A ET AL: "Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia" JOURNAL OF INTERNAL MEDICINE, vol. 243, no. 2, February 1998 (1998-02), pages 163-170, XP002371430 ISSN: 0954-6820
  • NORDOY A ET AL: "EFFECTS OF ATORVASTATIN AND OMEGA-3 FATTY ACIDS ON LDL SUBFRACTIONS AND POSTPRANDIAL HYPERLIPEMIA IN PATIENTS WITH COMBINED HYPERLIPEMIA" NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, MILAN, IT, vol. 11, no. 1, February 2001 (2001-02), pages 7-16, XP008060643 ISSN: 0939-4753
  • YANO TAKASHI ET AL.: "Effects of ethyl-all-cis-5,8,11,14,17-eicosapentaenoa te (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits" LIFE SCIENCES, vol. 61, no. 20, 1997, pages 2007-2015,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).